Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 02, 2025, titled ""Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials"".